EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease



Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease



Biology of Blood and Marrow Transplantation 11(4): 307-313



Current treatment of chronic graft-versus-host disease (cGVHD) with prednisone (PSE) alone or with added cyclosporine or tacrolimus still has a very high failure and complication rate, and new treatment approaches are needed for both primary and salvage therapy. Mycophenolate mofetil (MMF) is an immunosuppressive agent currently in use for acute graft-versus-host disease prophylaxis. To determine whether MMF had activity in the treatment of cGVHD, we added MMF to standard cyclosporine, tacrolimus, and/or PSE as salvage/second-line (n = 24) or first-line (n = 10) therapy in 34 patients. Nine (90%) of 10 patients receiving first-line and 18 (75%) of 24 receiving second-line MMF therapy responded. Twelve (35%) patients had a complete remission, 15 (44%) had a partial remission, 5 (15%) had stable disease, and only 2 (6%) had progressive disease. Out of 30 patients receiving PSE, 22 (73%) were able to decrease PSE doses (median decrease of 50%; range, 25%-100%). With a median follow-up of 24 months (range, 6-28 months), 29 (85%) patients are alive. Three patients had to discontinue MMF because of abdominal cramps within 3 months of starting treatment. These data suggest that MMF is an active, well-tolerated agent in the treatment of cGVHD and may have a beneficial effect on the survival of patients with this complication.

(PDF emailed within 0-6 h: $19.90)

Accession: 048920372

Download citation: RISBibTeXText

PMID: 15812396

DOI: 10.1016/j.bbmt.2005.01.011



Related references

Mycophenolate mofetil for the treatment of chronic graft versus host disease of the liver. Blood 94(10 SUPPL 1 PART 1): 159a, Nov 15, 1999

Treatment of acute and chronic graft versus host disease with mycophenolate mofetil. Blood 94(10 SUPPL 1 PART 2): 368b, Nov 15, 1999

The use mycophenolate mofetil in the treatment of refractory chronic graft versus host disease. Blood 92(10 SUPPL 1 PART 1-2): 346B, Nov 15, 1998

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 113(21): 5074-5082, 2009

Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Annals of Hematology 84(10): 681-685, 2005

Mycophenolate mofetil as salvage treatment for steroid-refractory chronic graft versus-host disease in children. Blood 98(11 Part 1): 398a, November 16, 2001

Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. International Journal of Hematology 83(1): 80-85, 2006

A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. International Journal of Hematology 91(3): 464-470, 2010

Mycophenolate mofetil (MMF) for refractory chronic graft versus host disease (cGvHD). Haematologica 88(8): Elt28; Author Reply Elt29-Elt28; Author Reply Elt29, 2003

Salvage therapy with mycophenolate mofetil and FK-506 for refractory chronic graft-versus-host disease. Blood 92(10 SUPPL 1 PART 1-2): 457A, Nov 15, 1998

Response to mycophenolate mofetil therapy for refractory chronic graft-versus-host disease. Haematologica 88(7): 837-839, July, 2003

Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplantation 24(5): 517-520, Sept 1, 1999

Treatment of severe bone marrow graft versus host disease with mycophenolate mofetil. Journal of Allergy & Clinical Immunology 107(2): S297, February, 2001

Mycophenolate mofetil as rescue therapy for high-risk steroid-refractory chronic graft versus-host-disease. Pediatric Research 53(4 Part 2): 275A, April, 2003

Conversion from Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium (myfortic) in a Patient with Graft-versus-host Disease. Drugs 66(2 Supplement): 29-31, 2006